JE
MBRX icon

JMAC Enterprises’s Moleculin Biotech MBRX Stock Holding History

JMAC Enterprises’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-35
Closed -$11.3K – 171
2023
Q4 		$11.3K Hold
35
– – ﹤0.01% 170
2023
Q3 		$5.61K Hold
35
– – ﹤0.01% 161
2023
Q2 		$7.6K Hold
35
– – ﹤0.01% 171
2023
Q1 		$12.6K Hold
35
– – ﹤0.01% 176
2022
Q4 		$13.9K Hold
35
– – ﹤0.01% 174
2022
Q3 		$14K Hold
35
– – ﹤0.01% 172
2022
Q2 		$19K Buy
+35
New +$20.4K ﹤0.01% 176

Other funds holding MBRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AWM
Atticus Wealth Management Palm Beach Gardens, Florida $420M AUM 23.31% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FIM
FWL Investment Management Dallas, Texas $456M AUM 60.63% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.33B AUM 24% 1-Year Est. Return

JMAC Enterprises's MBRX Position: Q1 2024 in Review

JMAC Enterprises sold out of Moleculin Biotech (MBRX) in Q1 2024, closing a stake of 35 shares — an estimated $11.3K sold.

JMAC Enterprises first reported a position in MBRX in Q2 2022 and held it in 7 quarters. The position peaked at $19K in Q2 2022. 15 funds tracked by Wall St. Rank hold MBRX as of Q1 2024.

  • JMAC Enterprises reported no remaining Moleculin Biotech position as of Q1 2024 after selling out during the quarter.
  • JMAC Enterprises sold 35 Moleculin Biotech shares in Q1 2024, an estimated $11.3K.
  • JMAC Enterprises first reported a position in Moleculin Biotech in Q2 2022 and held it in 7 quarters.
  • JMAC Enterprises's Moleculin Biotech position peaked at $19K in Q2 2022.
  • 15 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2024.

Based on JMAC Enterprises's 13F filing for Q1 2024, filed 30 Apr 2024.